Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.38 |
| ▸ | CDK9 | P50750 | 5/20 | 0.38 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333904 | 0.91 | SIRT2 (0.44) | SIRT2CCNT1CDK9CAMK2DCCNA2 | |
| SCHEMBL5341756 | 0.80 | SIRT2 (0.38) | SIRT2 | |
| SCHEMBL5339288 | 0.80 | MAOB (0.38) | SIRT2 | |
| SCHEMBL5341440 | 0.76 | CCNT1 (0.53) | SIRT2CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL6575073 | 0.73 | SIRT2 (0.49) | SIRT2CCNT1CDK9CAMK2DCCNA2 | |
| SCHEMBL5339048 | 0.73 | SIRT2 (0.53) | SIRT2CCNT1CDK9CAMK2DCCNA2 | |
| SCHEMBL5337035 | 0.69 | GHSR (0.34) | — | |
| SCHEMBL5347008 | 0.69 | GHSR (0.33) | — | |
| SCHEMBL6575546 | 0.67 | PIM1 (0.53) | SIRT2CCNT1CDK9CAMK2DCCNA2 | |
| SCHEMBL5682638 | 0.66 | SIRT2 (0.41) | SIRT2CCNT1CDK9CAMK2DGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202255-B2 | Substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2007-04-10 | — | — | US | disclosed |
| EP-1587810-B1 | NOVEL SUBSTITUTED 1,4|BENZODIOXINO 2,3-E|ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-02-23 | — | — | US | disclosed |
| EP-1587810-A1 | NOVEL SUBSTITUTED 1,4]BENZODIOXINO 2,3-E]ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004037831-A1 | NOVEL SUBSTITUTED[1,4]BENZODIOXINO[2,3-E]ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | CYP11B2, CYP2F1, CYP3A43 | SIRT2 2042/4885CCNT1 574/4885CDK9 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.